Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 04:00PM ET
32.20
Dollar change
-0.75
Percentage change
-2.28
%
Index- P/E- EPS (ttm)-2.32 Insider Own0.94% Shs Outstand65.84M Perf Week-3.65%
Market Cap2.12B Forward P/E- EPS next Y-1.15 Insider Trans0.00% Shs Float65.28M Perf Month-10.75%
Income-152.81M PEG- EPS next Q-0.22 Inst Own29.31% Short Float2.23% Perf Quarter-20.71%
Sales582.71M P/S3.64 EPS this Y-132.26% Inst Trans-0.89% Short Ratio12.04 Perf Half Y-6.12%
Book/sh42.12 P/B0.76 EPS next Y-2.45% ROA-3.19% Short Interest1.46M Perf Year-11.78%
Cash/sh61.24 P/C0.53 EPS next 5Y47.44% ROE-5.65% 52W Range31.86 - 45.21 Perf YTD-20.79%
Dividend Est.- P/FCF- EPS past 5Y- ROI-5.49% 52W High-28.78% Beta0.25
Dividend TTM- Quick Ratio8.78 Sales past 5Y15.83% Gross Margin96.76% 52W Low1.07% ATR (14)0.66
Dividend Ex-Date- Current Ratio8.91 EPS Y/Y TTM-3035.40% Oper. Margin-37.29% RSI (14)25.96 Volatility1.20% 1.48%
Employees1338 Debt/Eq0.01 Sales Y/Y TTM-7.12% Profit Margin-26.22% Recom2.50 Target Price46.56
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q29.37% Payout0.00% Rel Volume2.50 Prev Close32.95
Sales Surprise367.82% EPS Surprise220.78% Sales Q/Q-4.78% EarningsFeb 22 AMC Avg Volume120.87K Price32.20
SMA20-5.31% SMA50-11.91% SMA200-15.09% Trades Volume302,687 Change-2.28%
Date Action Analyst Rating Change Price Target Change
TodayDowngrade BofA Securities Neutral → Underperform $41 → $31
Mar-07-24Resumed Morgan Stanley Equal-Weight $38
Aug-24-23Downgrade Citigroup Buy → Neutral
May-05-23Upgrade Raymond James Mkt Perform → Outperform
Jan-23-23Upgrade Jefferies Underperform → Hold $49 → $47.20
Nov-07-22Downgrade Raymond James Outperform → Mkt Perform
Sep-09-22Downgrade Morgan Stanley Overweight → Equal-Weight $80 → $61
Jan-27-22Upgrade Citigroup Neutral → Buy
Aug-19-21Downgrade Barclays Overweight → Equal Weight
Aug-06-21Downgrade Deutsche Bank Buy → Hold
Today 04:01PM
Mar-26-24 04:01PM
Mar-18-24 09:35AM
Mar-17-24 05:20PM
Feb-24-24 08:30AM
04:01PM Loading…
Feb-22-24 04:01PM
04:01PM
Feb-15-24 04:01PM
Feb-05-24 07:00AM
Jan-31-24 04:01PM
Jan-04-24 04:01PM
Jan-03-24 04:01PM
04:01PM
Jan-02-24 01:00AM
Dec-19-23 04:01PM
12:00PM Loading…
Dec-09-23 12:00PM
Dec-07-23 04:01PM
Nov-06-23 10:32AM
07:45AM
Nov-02-23 04:01PM
Oct-30-23 04:01PM
Sep-19-23 04:01PM
Aug-28-23 04:01PM
Aug-03-23 04:01PM
Jun-15-23 04:01PM
Jun-12-23 04:01PM
Jun-05-23 04:01PM
May-23-23 04:01PM
May-22-23 04:01PM
May-05-23 04:01PM
04:01PM Loading…
May-04-23 04:01PM
May-02-23 04:01PM
Apr-26-23 04:01PM
Apr-25-23 04:01PM
Mar-30-23 04:30PM
Mar-23-23 04:01PM
Mar-20-23 04:01PM
Feb-27-23 04:01PM
Feb-23-23 04:01PM
Feb-09-23 04:01PM
Feb-08-23 04:01PM
Jan-10-23 04:01PM
Jan-03-23 04:01PM
Dec-23-22 04:01PM
Dec-22-22 04:01PM
Dec-16-22 09:55AM
Dec-13-22 01:00AM
Dec-08-22 09:35AM
Nov-11-22 07:15AM
Nov-08-22 04:01PM
Nov-04-22 04:01PM
Nov-03-22 04:01PM
Nov-02-22 07:15AM
Oct-17-22 01:30AM
Oct-06-22 04:01PM
Oct-03-22 04:01PM
Sep-29-22 03:59PM
Sep-27-22 04:01PM
Sep-13-22 10:21AM
Aug-29-22 04:01PM
Aug-24-22 04:01PM
Aug-18-22 04:01PM
Aug-08-22 04:01PM
Aug-04-22 04:01PM
Jun-29-22 09:40AM
Jun-22-22 06:39AM
Jun-21-22 04:03PM
Jun-20-22 04:01PM
Jun-09-22 09:55AM
Jun-02-22 09:40AM
Jun-01-22 04:01PM
May-25-22 04:01PM
May-24-22 09:35AM
May-16-22 09:40AM
May-11-22 09:47AM
May-09-22 03:30PM
May-06-22 04:01PM
May-05-22 04:01PM
Apr-28-22 09:40AM
Apr-26-22 04:01PM
Apr-04-22 09:10AM
Mar-28-22 02:01AM
Mar-24-22 04:17PM
04:17PM
Mar-18-22 05:01PM
Feb-24-22 04:01PM
Feb-03-22 04:01PM
Feb-02-22 04:01PM
Jan-27-22 06:07PM
10:15AM
07:50AM
Jan-26-22 06:01PM
04:40PM
04:01PM
Jan-18-22 04:01PM
Jan-14-22 11:42AM
Jan-13-22 04:01PM
Jan-06-22 09:30AM
Dec-24-21 12:38AM
Dec-18-21 12:38AM
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium.